About this trial
Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours. This intense pain gradually subsides, with significant relief usually occurring by the 2nd or 3rd postoperative day. The initial peak and subsequent decline in pain intensity highlight the importance of effective early pain management strategies to ensure patient comfort and recovery during this critical period. Inadequate management of postoperative pain can result in serious complications. Lidocaine is increasingly recognised as a vital adjunct in managing perioperative pain. Its efficacy extends beyond traditional local anaesthetic applications, as it also demonstrates analgesic, anti-hyperalgesic, and anti-inflammatory properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with hypnotic, sedative, anxiolytic, sympatholytic, and analgesic effects, while causing minimal respiratory depression
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age: 20-50 years, both sexes.
American Standards Association (ASA) physical status class II to III.
Body mass index (BMI) 35-50 kg m-².
Disqualifiers
Cardiac conduction disorders.
Cardiomyopathy.
Chronic opioid use.
Allergy to the studied medications.
Trial design
Parallel
Treatments tested in this trial
intravenous lidocaine
Other intervention20 patients will receive lidocaine infusion
intravenous dexmedetomidine
Other intervention20 patients will receive dexmedetomidine infusion
Treatment groups
Trial outcomes
Primary outcomes
visual analogue scale
at rest , movement
Secondary outcomes
time to first nalbuphine dose
minutes
patient satisfaction
• Poor = 1, fair = 2, good = 3, excellent = 4.
postoperative nalbuphine requirements
mg
postoperative complications
nausea , vomiting
Sponsors and contacts
Click on the lead sponsor to view all of their trials.